Topic:
Venture Capital
Latest Headlines
Latest Headlines
Biotech VC firm Frazier Healthcare closes in on $300M fund
Frazier Healthcare has grabbed commitments of $281.8 million toward a targeted $300 million for the venture firm's seventh fund, according to an SEC filing. The firm seeks to raise half as much as the $600 million it secured for its previous fund launched in 2008, yet the crew at Frazier have done well enough to survive a serious drought fundraising for VC outfits.
Trevena lands $430M Forest deal, $60M venture round as heart drug heads to PhIIb
With its lead drug poised to begin a Phase IIb study for acute heart failure, Trevena grabbed a $30 million investment from Forest Laboratories, which also picked up an option to snag global rights to the biotech's lead therapy with a deal that includes a $430 million potential payout.
Startup biotech charges into PhII with $23M bankroll for rare disease drugs
A little more than a year ago, the startup crew at Lumena Pharmaceuticals was based in North Carolina and working on a new drug for diabetics. But things have changed. The company moved to San Diego, refocused its lead program on a rare liver disease and today announced that it had rounded up $23 million in Series A cash from a trio of venture groups.
NGM raises $13M for cardio/metabolic R&D work
The company, which includes Genentech legend Art Levinson on its board, has been engaged in basic scientific research for the past 5 years, with a special focus on cardio/metabolic work.
Astellas, VCs stake virtual biotech spinout with $15M and a PhII program
Astellas and a pair of venture companies have joined forces to launch a spinout virtual biotech which will pick up mid-stage research work on an experimental therapy for nocturia.
AltheRx Pharma adds $15M, new CEO and ex-AstraZeneca exec
After gaining its lead asset from GlaxoSmithKline, AltheRx Pharmaceuticals has made a series of leadership changes through a restructuring plan that features a $15 million investment led by Becker Ventures.
Biotech Symphogen tacks on $53.7M to big venture round after Merck Serono deal
Symphogen has replenished its coffers with 41 million euros ($53.7 million) as the Danish biotech makes progress with next-generation antibody drugs for treating cancer. The latest capital infusion adds to 100 million euros ($130.9 million) that the company previously raised in 2011 for the round, giving the company about 100 million euros in cash as of today, according to the group's press release.
Capital Royalty launches $805M fund for biotech, healthcare deals
Houston-based Capital Royalty has pieced together an $805 million fund to back a new package of loans and royalty deals with biotechs, pharma and other healthcare companies looking for some "alternative" sources of financing.
Billionaire Kirk grabs $150M round for synthetic biology deals at Intrexon
A day after striking the latest in a series of its special "channel" collaborations, Intrexon has reloaded its bank account with a fresh $150 million infusion of cash, with significant added contributions from billionaire founder R.J. Kirk and his venture fund, Third Security.
Atlas Venture targets early-stage biotech bets with new $265M fund
After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9 th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack of capital to fuel startups in biotech and other high-risk-and-reward sectors.
